<DOC>
	<DOCNO>NCT02180438</DOCNO>
	<brief_summary>There critical need safe effective antiretroviral treatment ( ART ) regimens HIV-2 infection . This especially true West Africa , vast majority 1-2 million individual infected HIV-2 live access effective ART HIV-2 limit . HIV-2 intrinsically resistant non-nucleoside reverse transcriptase inhibitor ( NNRTI ) fusion inhibitor enfuvirtide ( T-20 ) mutation confer broad resistance nucleoside/nucleotide reverse transcriptase inhibitor ( NRTI ) frequently observe HIV-2 patient receive ART . Although antiretroviral protease inhibitor ( PI ) use effectively treat HIV- 2 , HIV-1 HIV-2 also exhibit important difference susceptibility study indicate saquinavir ( SQV ) , lopinavir ( LPV ) , darunavir ( DRV ) potent PI 's HIV-2 replication cross-resistance frequent . Although increase body evidence support potential utility integrase inhibitor ( INI ) HIV-2 , clinical trial assess effectiveness routinely available resource-limited setting . These limitation present major challenge HIV-2 treatment , particularly area prevalent . This study 1st use STRIBILD ( elvitegravir ( EVG ) , cobicistat ( COBI ) , emtricitabine ( FTC ) , tenofovir disoproxil fumarate ( TDF ) ) , INI-based single tablet regimen , HIV-2 infect adult West Africa . The investigator hypothesize STRIBILD safe effective ART HIV-2 infection . The Specific Aims study : AIM 1 : A pilot , open label , 48 week trial STRIBILD ( elvitegravir , cobicistat , emtricitabine , tenofovir disoproxil fumarate ) 30 ARV-naïve HIV-2 Infected Adults Dakar , Senegal . AIM 2 : Determination genotypic phenotypic HIV-2 antiretroviral resistance individual virologic failure ( HIV-2 plasma RNA &gt; 250 copies/ml ) participate 48 week trial STRIBILD</brief_summary>
	<brief_title>An Open Label Trial Stribild Antiretroviral ( ARV ) -naïve HIV-2 Infected Adults Dakar , Senegal</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Written inform consent Age &gt; 18 year old HIV2 Infection ( confirm DetermineTM &amp; Immunocomb II ) ARVnaïve CD4 count &lt; 750 cells/mm3 and/or WHO Stage 3 4 disease Anticipate residing Dakar area duration study Pregnancy Breast feed HIV1 HIV1/HIV2 dual infection Known allergy contraindication Elvitegravir , Cobicistat , Emtricitabine , Tenofovir DF Active Tuberculosis ( STRIBILD contraindicate rifampin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV-2</keyword>
</DOC>